
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10859246/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Correspondence on â€~No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related †physician-reported spondylitis'?'. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.5	3
2	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the Rheumatic Diseases, 2018, 77, 1295-1302.	0.5	275
3	Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Translational Research, 2016, 167, 138-151.	2.2	34
4	Urinary mRNA in Systemic Lupus Erythematosus. Advances in Clinical Chemistry, 2013, 62, 197-219.	1.8	4
5	Immunopathological Roles of Cytokines, Chemokines, Signaling Molecules, and Pattern-Recognition Receptors in Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	56
6	Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Research and Therapy, 2012, 14, R80.	1.6	28
7	Glomerular and tubulointerstitial miRâ€638, miRâ€198 and miRâ€146a expression in lupus nephritis. Nephrology, 2012, 17, 346-351.	0.7	99
8	Down-Regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production. PLoS ONE, 2011, 6, e23855.	1.1	19
9	Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: A prospective cohort study. Arthritis Care and Research, 2011, 63, 269-276.	1.5	32
10	Serum and Urinary Cell–free MiR-146a and MiR-155 in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2516-2522.	1.0	174
11	Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus — A Prospective Cohort Study. Journal of Rheumatology, 2010, 37, 330-340.	1.0	71
12	Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clinical Rheumatology, 2007, 26, 1495-1498.	1.0	192
13	Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection. Arthritis and Rheumatism, 2004, 50, 3619-3625.	6.7	145
14	Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scandinavian Journal of Rheumatology, 2002, 31, 296-300.	0.6	117